
Breast Cancer
Dana-Farber Cancer Institute Handbook
Mosby (Publisher)
Published on 29. June 2007
Book
Paperback/Softback
176 pages
978-0-7234-3432-0 (ISBN)
Description
Considerable progress is being made in the field of oncology, and the rapid expansion of available information can often make it difficult for the busy practitioner to know which decisions are most appropriate in a given circumstance. The success of the "Dana-Farber Cancer Institute Atlas of Diagnostic Oncology" has led to the development of a series of disease management handbooks designed to aid the clinician with his or her decision making in clinical practice. Written by highly eminent authors, "Breast Cancer" is produced in full color and is richly illustrated throughout, providing a review of each cancer including its incidence, epidemiology, etiology and histopathology, together with the clinical features. Diagnostic studies and current clinical and pathological staging are also given. Detailed tables are provided with histopathological classification, diagnostic studies and, when important, prognostic factors. Current therapies are also discussed in detail, together with useful algorithms to aid treatment decisions.
Practical issues relating to management are also given such as dealing with systemic and mucocutaneous reactions to chemotherapy, including alopecia, fatigue and extravasation.
Practical issues relating to management are also given such as dealing with systemic and mucocutaneous reactions to chemotherapy, including alopecia, fatigue and extravasation.
More details
Series
Language
English
Place of publication
London
United Kingdom
Publishing group
Elsevier Health Sciences
Target group
Professional and scholarly
The book is aimed at trainee oncologists and general physicians who manage cancer patients outside of specialist centers.
Illustrations
Approx. 150 illustrations (100 in full color)
Dimensions
Height: 215 mm
Width: 133 mm
ISBN-13
978-0-7234-3432-0 (9780723434320)
Copyright in bibliographic data and cover images is held by Nielsen Book Services Limited or by the publishers or by their respective licensors: all rights reserved.
Schweitzer Classification
Persons
Arthur T. Skarin, MD, FACP, FCCP, earned his MD from the State University of New York at Buffalo in 1961, and received postgraduate training in internal medicine at the Millard Fillmore Teaching Hospital in Buffalo. After a fellowship in hematology and oncology at Boston City Hospital, he joined Brigham and Women's Hospital and Dana-Farber Cancer Institute (DFCI) in 1970. He served as Clinical Director of the DFCI Hematology Laboratory as well as Chairman of the Laboratory Committee from 1970 to 1998. He established the multimodality thoracic oncology clinic in 1975 and has served as Medical Director since then. During that time he also was chair of the human protection committee (IRB) for 12 years and became Associate Professor of Medicine at Harvard Medical School. He has been the Principal Investigator (PI) as well as site PI on numerous clinical research Phase I, II and III trials, both at DFCI Partners Cancer Care and the Cancer and Leukemia Group B (CALGB). He was appointed a Research Subject Advocate (RSA) in 2002 for NIH funded studies at the Brigham and Women's Hospital General Clinical Research Center (GCRC) and DFCI. Dr. Skarin is a board member of the American Journal of Oncology Review, the Journal of Cinical Oncology, Hospital Physician and also president of the Massachusetts Society of Clinical Oncologists. He has published 150 original articles, 97 abstracts, 67 chapters in books and 4 books. Dr Wardley is a Consultant Medical Oncologist and Co-Chair of the Breast Disease Orientated Group at the Christie Hospital in Manchester. He is Clinical Research Lead for the Manchester Breast Centre and the Greater Manchester and Cheshire Breast Cancer Studies Group. He is a member of the National Cancer Research Institute Breast Cancer Studies Group, the Breast International Group, the Protocol Committee for the European Organisation for Research and Treatment of Cancer Breast Study Group and International Cancer Collaborative Group Steering Committee, as well as a member of the Association of Cancer Physicians Executive Committee. Dr Wardley is a graduate of Manchester University and received an MSc. and an MD in Oncology in 2000 and his FRCP in 2005. He has an active role in education of Specialist Trainees, medical students, nurses, pharmacists and allied professionals. He organised the 2005 ACP Summer School, and lectured at the 5th European School of Oncology Masterclass in Clinical Oncology. Dr Wardley is currently involved in development of novel areas for breast cancer research in Manchester in collaboration with international groups. He is a respected key note speaker and is a frequent presenter at both National and International conferences. He has published articles in leading journals such as the New England Journal of Medicine, Journal of Clinical Oncology and British Journal of Cancer, and is medical oncology specialty sub-editor for The Breast.
Content
Introduction The role of molecular probes and other markers in the diagnosis and characterization of malignancy Breast cancer: incidence, screening, histology and staging Treatment of breast cancer Systemic and mucocutaneous reactions to chemotherapy